S D Shnyder

Summary

Affiliation: University of Bradford
Country: UK

Publications

  1. ncbi request reprint Sodium pancratistatin 3,4-o-cyclic phosphate, a water-soluble synthetic derivative of pancratistatin, is highly effective in a human colon tumor model
    Steven D Shnyder
    J Nat Prod 71:321-4. 2008
  2. ncbi request reprint Reducing the cost of screening novel agents using the hollow fibre assay
    S D Shnyder
    Institute of Cancer Therapeutics, School of Health Studies, University of Bradford, Bradford BD7 1DP, UK
    Anticancer Res 26:2049-52. 2006
  3. ncbi request reprint Auristatin PYE, a novel synthetic derivative of dolastatin 10, is highly effective in human colon tumour models
    Steven D Shnyder
    Institute of Cancer Therapeutics, University of Bradford, Bradford BD7 1DP, UK
    Int J Oncol 31:353-60. 2007
  4. ncbi request reprint Development of a modified hollow fibre assay for studying agents targeting the tumour neovasculature
    S D Shnyder
    Cancer Research Unit, Tom Connors Cancer Research Centre, University of Bradford, Richmond Road, Bradford, UK
    Anticancer Res 25:1889-94. 2005
  5. ncbi request reprint Vinflunine
    Steven D Shnyder
    Cancer Research Unit, Tom Connors Cancer Research Centre, University of Bradford, Richmond Road, Bradford, BD7 1DP, UK
    IDrugs 7:851-9. 2004
  6. ncbi request reprint Vinflunine potentiates the activity of cisplatin but not 5-fluorouracil in a transplantable murine adenocarcinoma model
    S D Shnyder
    Cancer Research Unit, Tom Connors Cancer Research Centre, University of Bradford, Richmond Road, Bradford BD7 1DP, U K
    Anticancer Res 23:4815-20. 2003
  7. ncbi request reprint Combretastatin A-1 phosphate potentiates the antitumour activity of cisplatin in a murine adenocarcinoma model
    S D Shnyder
    Cancer Research Unit, Tom Connors Cancer Research Centre, University of Bradford, Richmond Road, Bradford BD7 1DP, U K
    Anticancer Res 23:1619-23. 2003
  8. ncbi request reprint Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumours
    S E Holwell
    Cancer Research Unit, University of Bradford, UK
    Anticancer Res 22:707-11. 2002
  9. ncbi request reprint Pharmacological and biological evaluation of a series of substituted 1,4-naphthoquinone bioreductive drugs
    Roger M Phillips
    Cancer Research Unit, Tom Connors Cancer Research Centre, University of Bradford, Bradford BD71DP, UK
    Biochem Pharmacol 68:2107-16. 2004
  10. ncbi request reprint Synthesis of cryptolepine analogues as potential bioreducible anticancer agents
    Scott Seville
    The School of Pharmacy, University of Bradford, Bradford, West Yorkshire BD7 1DP, UK
    Bioorg Med Chem 15:6353-60. 2007

Collaborators

Detail Information

Publications21

  1. ncbi request reprint Sodium pancratistatin 3,4-o-cyclic phosphate, a water-soluble synthetic derivative of pancratistatin, is highly effective in a human colon tumor model
    Steven D Shnyder
    J Nat Prod 71:321-4. 2008
    ..The mechanism of action of 1 and 2 appears to be similar. Thus compound 2, being considerably more soluble than 1, has good potential as an anticancer agent, and further investigation is warranted...
  2. ncbi request reprint Reducing the cost of screening novel agents using the hollow fibre assay
    S D Shnyder
    Institute of Cancer Therapeutics, School of Health Studies, University of Bradford, Bradford BD7 1DP, UK
    Anticancer Res 26:2049-52. 2006
    ..The HFA can thus be performed in these less expensive and more easily available mice with the implication of considerable savings to the preclinical cancer pharmacology community...
  3. ncbi request reprint Auristatin PYE, a novel synthetic derivative of dolastatin 10, is highly effective in human colon tumour models
    Steven D Shnyder
    Institute of Cancer Therapeutics, University of Bradford, Bradford BD7 1DP, UK
    Int J Oncol 31:353-60. 2007
    ..Auristatin PYE was more effective in the DLD-1 and COLO 205 models than dolastatin 10, with anti-tumour effects mediated through vascular shutdown. These data suggest that auristatin PYE has good potential as an anti-cancer agent...
  4. ncbi request reprint Development of a modified hollow fibre assay for studying agents targeting the tumour neovasculature
    S D Shnyder
    Cancer Research Unit, Tom Connors Cancer Research Centre, University of Bradford, Richmond Road, Bradford, UK
    Anticancer Res 25:1889-94. 2005
    ..Previous studies have shown extensive vascularisation surrounding subcutaneously implanted fibres when the duration of the US National Cancer Institute (NCI) hollow fibre assay was prolonged...
  5. ncbi request reprint Vinflunine
    Steven D Shnyder
    Cancer Research Unit, Tom Connors Cancer Research Centre, University of Bradford, Richmond Road, Bradford, BD7 1DP, UK
    IDrugs 7:851-9. 2004
    ..Pierre Fabre SA, in collaboration with Bristol-Myers Squibb Co, is developing vinflunine, a fluorinated vinca alkaloid, as a potential anticancer agent...
  6. ncbi request reprint Vinflunine potentiates the activity of cisplatin but not 5-fluorouracil in a transplantable murine adenocarcinoma model
    S D Shnyder
    Cancer Research Unit, Tom Connors Cancer Research Centre, University of Bradford, Richmond Road, Bradford BD7 1DP, U K
    Anticancer Res 23:4815-20. 2003
    ..Previous studies with compounds showing similar effects in combination with standard anti-cancer agents have demonstrated an improved efficacy relative to the standard agents...
  7. ncbi request reprint Combretastatin A-1 phosphate potentiates the antitumour activity of cisplatin in a murine adenocarcinoma model
    S D Shnyder
    Cancer Research Unit, Tom Connors Cancer Research Centre, University of Bradford, Richmond Road, Bradford BD7 1DP, U K
    Anticancer Res 23:1619-23. 2003
    ..Previous studies with CA4P in combination with standard anti-cancer agents have demonstrated improved efficacy relative to the standard agents...
  8. ncbi request reprint Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumours
    S E Holwell
    Cancer Research Unit, University of Bradford, UK
    Anticancer Res 22:707-11. 2002
    ..These data suggest this compound may have potential for clinical development...
  9. ncbi request reprint Pharmacological and biological evaluation of a series of substituted 1,4-naphthoquinone bioreductive drugs
    Roger M Phillips
    Cancer Research Unit, Tom Connors Cancer Research Centre, University of Bradford, Bradford BD71DP, UK
    Biochem Pharmacol 68:2107-16. 2004
    ..In conclusion, compound 3 is a promising lead compound that may target both aerobic and hypoxic fractions of NQO1-rich tumours and further studies to elucidate its mechanism of action and improve solubility are warranted...
  10. ncbi request reprint Synthesis of cryptolepine analogues as potential bioreducible anticancer agents
    Scott Seville
    The School of Pharmacy, University of Bradford, Bradford, West Yorkshire BD7 1DP, UK
    Bioorg Med Chem 15:6353-60. 2007
    ..This study has identified novel substrates for both NQO1 and NQO2 and further work on nitrocryptolepine derivatives as a lead towards novel anticancer agents would be worthwhile...
  11. ncbi request reprint Polysialyltransferase: a new target in metastatic cancer
    R A Falconer
    Institute of Cancer Therapeutics, School of Life Sciences, University of Bradford, Bradford BD7 1DP, UK
    Curr Cancer Drug Targets 12:925-39. 2012
    ..Selective inhibition of polySTs therefore presents a therapeutic opportunity to inhibit tumour invasion and metastasis...
  12. ncbi request reprint The hollow fibre model--facilitating anti-cancer pre-clinical pharmacodynamics and improving animal welfare
    Marie Suggitt
    Institute of Cancer Therapeutics, University of Bradford, Bradford, BD7 1DP, UK
    Int J Oncol 29:1493-9. 2006
    ....
  13. ncbi request reprint Synthesis of DNA-directed pyrrolidinyl and piperidinyl confined alkylating chloroalkylaminoanthraquinones: potential for development of tumor-selective N-oxides
    Klaus Pors
    Institute of Cancer Therapeutics, University of Bradford, West Yorkshire, BD7 1DP, United Kingdom
    J Med Chem 49:7013-23. 2006
    ..Derivatization of the potent DNA cross-linking agent 15 to an N-oxide resulted in loss of the DNA unwinding, DNA interstrand cross-linking and cytotoxic activity of the parent molecule...
  14. pmc Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases
    Jennifer M Atkinson
    Institute of Cancer Therapeutics, University of Bradford, Bradford, West Yorkshire, UK
    Cancer Res 70:6902-12. 2010
    ..Our findings support the clinical development of ICT2588, which achieves selective VDA targeting based on MT-MMP activation in the tumor microenvironment...
  15. ncbi request reprint Synthesis of some cryptolepine analogues, assessment of their antimalarial and cytotoxic activities, and consideration of their antimalarial mode of action
    Onyeka Onyeibor
    The School of Pharmacy, Department of Biomedical Sciences and Tom Connors Cancer Research Centre, University of Bradford, West Yorkshire, BD7 1DP, UK
    J Med Chem 48:2701-9. 2005
    ..No correlation was seen (r(2) = 0.0781) suggesting that the potent antimalarial activity of compounds such as 15 involves other mechanisms in addition to the inhibition of hemozoin formation...
  16. ncbi request reprint Use of the hollow fibre assay for studies of tumor neovasculature
    Steven D Shnyder
    Institute of Cancer Therapeutics, University of Bradford, Bradford, UK
    Methods Mol Biol 467:331-42. 2009
    ..The neovasculature is developed as a consequence of the presence of tumor cells encapsulated in hollow fibres, which are transplanted subcutaneously in the dorsal flanks of mice...
  17. ncbi request reprint Triplex profiling of functionally distinct chaperones (ERp29/PDI/BiP) reveals marked heterogeneity of the endoplasmic reticulum proteome in cancer
    Steven D Shnyder
    Department of Biochemistry, University of Otago, New Zealand
    J Proteome Res 7:3364-72. 2008
    ....
  18. ncbi request reprint Design, synthesis, and biophysical and biological evaluation of a series of pyrrolobenzodiazepine-poly(N-methylpyrrole) conjugates
    Geoff Wells
    Cancer Research UK Gene Targeted Drug Design Research Group, The School of Pharmacy, University of London, 29 39 Brunswick Square, London WC1N 1AX, UK
    J Med Chem 49:5442-61. 2006
    ..50a-f were shown to have good cellular/nuclear penetration properties, and a degree of correlation between cytotoxicity and DNA-binding affinity was observed...
  19. ncbi request reprint Secretory phospholipase A2 as a tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids
    Simon S Jensen
    LiPlasome Pharma A S, Technical University of Denmark, DK 2800 Lyngby, Denmark
    Mol Cancer Ther 3:1451-8. 2004
    ..This new approach also provides a promising system for tumor-selective delivery and release of conventional chemotherapeutics encapsulated in the sPLA2-degradable prodrug liposomes...
  20. ncbi request reprint Heparin octasaccharides inhibit angiogenesis in vivo
    Jurjees Hasan
    Cancer Research UK, Department of Medical Oncology, Manchester, UK
    Clin Cancer Res 11:8172-9. 2005
    ..Here, we present the first in vivo study of size-fractionated heparin oligosaccharides in four models of angiogenesis that are progressively less dependent on fibroblast growth factor-2...
  21. ncbi request reprint Guaianolide sesquiterpenes from Pulicaria crispa (Forssk.) Oliv
    Michael Stavri
    Centre for Pharmacognosy and Phytotherapy, The School of Pharmacy, University of London, 29 39 Brunswick Square, London WC1N 1AX, UK
    Phytochemistry 69:1915-8. 2008
    ..Compound 3 exhibited weak antimycobacterial activity against Mycobacterium phlei with a minimum inhibitory concentration of 0.52 mM and cytotoxicity (IC50 of 5.8+/-0.2 microM) in a human bladder carcinoma cell line, EJ-138...